Table 4 Clinical trials of Menin inhibitors

Revumenib (SNDX-5613)

Revumenib with Azacitidine + Venetoclax

Patients with NPM1-mutated or KMT2A-rearranged AML

Phase 3

415

NCT06652438

Not yet recruiting

Revumenib

Patients with KMT2A-Rearranged or NPM1-Mutated Acute Leukemia After AHSCT

Phase 1

27

NCT06575296

Not yet recruiting

Revumenib With 7 + 3 + Midostaurin

AML

Phase 1

22

NCT06313437

Not yet recruiting

Revumenib and Venetoclax

AML MRD positive

Phase 2

8

NCT06284486

Recruiting

Revumenib

Leukemia Associated with Upregulation of HOX Genes

Phase 2

15

NCT06229912

Recruiting

Revumenib and Gilteritinib

R/R FLT3-Mutated AML and Concurrent MLL-Rearrangement or NPM1 Mutation

Phase 1

30

NCT06222580

Recruiting

Revumenib, Azacitidine, and Venetoclax

in Pediatric and Young Adult Patients With R/R AML

Phase 1

24

NCT06177067

Recruiting

Revumenib + Daunorubicin and Cytarabine

Newly Diagnosed AML Patients with Changes in NPM1 or MLL/​KMT2A Gene

Phase 1

28

NCT05886049

Recruiting

Revumenib in Combination with Chemotherapy

Patients Diagnosed with R/R Leukemia

Phase 2

78

NCT05761171

Recruiting

Radiolabeled Revumenib

Adults with Acute Leukemia

Phase 1

8

NCT05406817

Recruiting

Revumenib in Combination with Chemotherapy

Participants With R/R Acute Leukemia

Phase 1

30

NCT05326516

Completed

Revumenib

R/R Leukemias Including Those with an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

Phase 1/2

413

NCT04065399

(AUGMENT-101)

Recruiting

Ziftomenib (KO-539)

Ziftomenib With Venetoclax and Gemtuzumab

Pediatric Patients With AML

Phase 1

22

NCT06448013

Not yet recruiting

Ziftomenib

Maintenance Post Allo-HCT in AML with NPM1m and KMT2A-r

Phase 1

22

NCT06440135

Recruiting

Ziftomenib, Venetoclax and Azacitidine

in Pediatric R/R Acute Leukemias

Phase 1

22

NCT06397027

Not yet recruiting

Ziftomenib in Combination with Chemotherapy

Children with R/R Acute Leukemia

Phase 1

20

NCT06376162

Not yet recruiting

Safety and Tolerability of Ziftomenib Combinations

KMT2A-r or NPM1-m R/R AML

Phase 1

171 e

NCT06001788

Recruiting

Ziftomenib with Venetoclax/​Azacitidine, Venetoclax, or 7 + 3

Patients with AML

Phase 1

212

NCT05735184

Recruiting

Ziftomenib

Patients With R/R AML

Phase 1/2

199

NCT04067336

Recruiting

DSP-5336

DSP-5336

R/R AML/ ALL with or Without KMT2A-r or NPM1-m

Phase 1/2

70

NCT04988555

Recruiting

DS-1594b

DS-1594bWith or Without Azacitidine, Venetoclax, or Mini-HCVD

R/R AML or ALL

Phase 1/2

17

NCT04752163

Completed

Bleximenib (JNJ-75276617)

Bleximenib in Combination with Conventional Chemotherapy

Pediatric and Young Adult Participants with Relapsed/Refractory Acute Leukemias

Phase 1

0

NCT05521087

Withdrawn

Bleximenib in Combination with Directed Therapies

Patients with AML

Phase 1

200

NCT05453903

Recruiting

Bleximenib

patients With Acute Leukemia

Phase 1/2

400

NCT04811560

Recruiting

BMF-219

BMF-219

Adult Patients With AML, ALL (With KMT2A/MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL

Phase 1

177

NCT05153330

Recruiting

BN104

BN104

Acute Leukemia

Phase 1/2

90

NCT06052813

Recruiting